Growth across geographies keeps analysts positive on Aurobindo Pharma

business-standard | May 30, 2019

Growth across geographies keeps analysts positive on Aurobindo Pharma
In a quarter which saw its peers struggle, Aurobindo Pharma put out a strong March quarter performance. The company saw a 30.7 per cent growth in revenues, led by a strong 42.7 per cent growth in US sales.The geography is its single largest, accounting for 47 per cent of overall revenues. This was largely driven by the higher margin injectables business growth, with a ramp-up in antibacterial Ertapenem injection and new launches. The company launched 15 products, including four injectables in the fourth quarter of 2018-19 (FY19). Aurobindo also completed acquisition of seven branded oncology injectable products from Spectrum Pharmaceuticals, Inc.In addition to the March quarter results, easing of regulatory worries and attractive valuations, too, have led to an improving sentiment for the stock. Analysts expect the company to maintain a strong growth momentum in the US and Europe, led by acquisitions as well as base business.Among the key triggers for the stock is the company’s limited-competition niche injectable portfolio. The portfolio achieved the targeted 30 per cent growth in FY19 and is expected to continue growing at a similar pace for another three years, led by new approvals (12-15 products in 2019-20, or FY20). Reliance Securities expects this capacity expansion to boost Aurobindo’s overall profitabilityThe company is also expected to complete the acquisition of Sandoz’s derma and oral solid business by the second quarter (Q2) of FY20, which analysts feel will scale up Aurobindo’s US operations significantly. Elara Capital expects the incorporation of Sandoz business to increase the company’s 2020-21 earnings by 10 per cent.For FY20, analysts expect the sterile portfolio to drive bulk of the growth, along with the consolidation of Sandoz as well as the Spectrum portfolios.

Spotlight

Infographic includes essential insights into the state of the global inhalation device markets.

Related News

BUSINESS INSIGHTS

Orsini Specialty Pharmacy Selected By Sanofi As A Limited Distribution Partner For Nexviazyme®

Orsini Specialty Pharmacy | September 28, 2021

Orsini Specialty Pharmacy, the leading independent specialty pharmacy focused on rare diseases and gene therapies, announced that Sanofi has selected it as a limited distribution partner for Nexviazyme® (avalglucosidase alfa-ngpt). Nexviazyme, an enzyme replacement therapy (ERT), is used for treating patients one year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency). This progressive and debilitating muscle disorder impairs a person's ability to move and breathe. For more information about Nexviazyme, please see the Full Prescribing Information. Pompe disease affects an estimated 3,500 people in the United States. It can present as infantile-onset Pompe disease (IOPD), the most severe form of Pompe disease with rapid onset in infancy, and late-onset Pompe disease (LOPD), which progressively damages muscles over time. LOPD symptoms may present at any age. However, due to the broad spectrum of clinical presentations and progressive nature of the disease, it can take seven to nine years before patients receive an accurate diagnosis. As the disease progresses, people with LOPD may require mechanical ventilation to help with breathing or a wheelchair to assist with mobility. Orsini's dedicated Pompe Disease Care Team's number one priority is providing exceptional care and compassionate support to patients and their families, We are proud to expand our partnership with Sanofi and add Nexviazyme to the growing number of enzyme replacement therapies we dispense to patients with rare diseases. - Mike Fieri, Orsini's Founder and Chief Executive Officer. About Orsini Specialty Pharmacy Providing patients with comprehensive and compassionate care since 1987, Orsini is the leading independent specialty pharmacy focused on rare diseases, gene therapies, and complex conditions. Orsini's high-touch care model centers around experienced, therapy-specific care teams that provide personalized care to patients based on their specific conditions and treatments. The company's comprehensive solutions include medication adherence programs, data analytics, customized manufacturer programs, and nationwide nursing coverage for convenient in-home infusion services. Headquartered in Elk Grove Village, IL, Orsini Specialty Pharmacy holds accreditations with URAC, the Accreditation Commission for Health Care (ACHC), ACHC's Distinction in Rare Diseases and Orphan Drugs, The Joint Commission, and the National Association of Boards of Pharmacy (NABP).

Read More

CVS Pharmacy is testing self-driving vehicles for medication delivery

Fiercehealthcare | June 02, 2020

CVS Health began testing drone delivery last year. Now, the company is moving on to try self-driving vehicles. The pharmacy retail giant is working with autonomous vehicle startup Nuro to test prescription delivery in the Houston market. Nuro, which was founded by two ex-Google engineers, will use its fleet of autonomous vehicles to deliver prescriptions and essentials to CVS Pharmacy customers. The deliveries will start this month and will come at no extra charge to CVS customers in Houston. “We are seeing an increased demand for prescription delivery,” said Ryan Rumbarger, senior vice president for store operations at CVS Health. “We want to give our customers more choice in how they can quickly access the medications they need when it’s not convenient for them to visit one of our pharmacy locations.”

Read More

PHARMA TECH

Pfizer, BioNTech COVID-19 vaccine works in more contagious coronavirus variants

Pfizer | January 11, 2021

Newly emerged variants of the novel coronavirus have sparked a key question: Will existing COVID-19 vaccines be less effective against them? But scientists have preliminary data showing that may not be the case, at least for Pfizer and BioNTech’s shot. Researchers from the University of Texas and Pfizer found that, in lab dishes, the vaccine was able to neutralize an engineered version of a variant, which bears an N501Y mutation in its spike protein. The finding was published in bioRxiv and hasn’t been peer-reviewed. Variants of coronavirus with this mutation were first discovered in the U.K. and South Africa and immediately grabbed global attention because they are more contagious. Currently available COVID vaccines—including Pfizer and BioNTech’s Comirnaty, or BNT162b2—target the spike protein of SARS-CoV-2, the coronavirus behind COVID-19. The N501Y mutation improves the ability of the virus’ spike protein to bind to its receptor on human cells, making it easier to gain entry for infection. To test whether Comirnaty worked against the mutation, the scientists collected antibodies from 20 vaccinated trial participants and compared their ability to kill off the engineered virus with the N501Y mutation to their ability to neutralize the strain on which Pfizer and BioNTech based Comirnaty.

Read More

Spotlight

Infographic includes essential insights into the state of the global inhalation device markets.